Lucía Deiros Bronte

Dr. Lucía Deiros Bronte

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
CLCarlos Labrandero
Carlos Labrandero
LBLucía Deiros Bronte
Lucía Deiros Bronte
CACésar Abelleira
César Abelleira
VAViviana Arreo
Viviana Arreo
EBEnrique J. Balbacid
Enrique J. Balbacid
FGFederico Gutiérrez-Larraya
Federico Gutiérrez-Larraya
The CardioMEMS is an implantable device for hemodynamic monitoring approved by the US Food and Drug Administration for adult patients with heart failure. It has been used in the adult population without structural heart disease and with congenital heart diseases, but we do not have data in the pediatric population. We report the initial single-center experience of the CardioMEMS implantation in children. Feasibility of device implantation, procedural outcomes, and clinical utility in the pediatric population were evaluated. The CardioMEMS device was implanted without technical complications in 8 pediatric patients (mean age 7 years and mean weight 27.9 kg) with pulmonary hypertension (6/8, 75%) and heart failure (2/8, 25%). The device was delivered via femoral access in 7 (85%) patients and implanted in the left pulmonary artery in 7 (85%). The noninvasive recording of pulmonary pressures in patients with pulmonary hypertension allowed the monitoring of the evolution of mean pulmonary artery pressure, intensifying vasodilator treatment, and avoiding control cardiac catheterizations. In patients with heart failure, pulmonary hemodynamic monitoring guided the decongestive treatment prior to heart transplantation. The implantation of CardioMEMS in the pediatric population is a feasible procedure that allows the noninvasive hemodynamic monitoring of patients with heart failure and pulmonary hypertension. Its implementation in selected patients aids in outpatient follow-up and therapeutic management of patients with complex cardiac conditions, avoiding invasive procedures that require hospitalization. Further large-scale studies in the pediatric population are recommended.

18 March 2026 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
LBLucía Deiros Bronte
Lucía Deiros Bronte
MZMercedes Aristoy Zabaleta
Mercedes Aristoy Zabaleta
NBNelson Mauricio Buitrago
Nelson Mauricio Buitrago
AUAngela Uceda
Angela Uceda
JDJesús Diez-Sebastián
Jesús Diez-Sebastián
FAFederico Gutierrez-Larraya Aguado
Federico Gutierrez-Larraya Aguado

30 August 2024 in Genes
Verified
Journal Article
Open access
PDF file
MAMelisa Cilio Arroyuelo
Melisa Cilio Arroyuelo
JTJair Antonio Tenorio
Jair Antonio Tenorio
LFLuis Fernandez
Luis Fernandez
APAlejandro Parra
Alejandro Parra
MCMario Cazalla
Mario Cazalla
PLPablo Lapunzina
Pablo Lapunzina
The 22q11.2 region is highly susceptible to genomic rearrangements leading to multiple genomic disorders, including 22q11.2 microdeletion syndrome (22q11.2 DS) (MIM# 188400), 22q11.2 microduplication syndrome (MIM# 608363), supernumerary der(22)t(11;22) syndrome (also known as Emanuel Syndrome; MIM# 609029), and Cat Eye Syndrome (MIM# 115470). In this study, we present data on causes of mortality, average age of death, and the existing associated risk factors in patients with 22q11.2 rearrangements. Our cohort included 223 patients (120 males and 103 females) with confirmed diagnoses of 22q11.2 rearrangements diagnosed through molecular techniques (FISH, MLPA, and CMA). Relatives from patients who have been molecularly confirmed with 22q11.2 rearrangements have also been added to the study, regardless of the presence or absence of symptoms. Of these 223 individuals, 21 (9.4%) died. Deceased patients’ rearrangements include 19 microdeletions, 1 microduplication, and 1 patient with a marker chromosome. The median age of death was 3 months and 18 days (ranging from 3 days to 34 years). There were 17 patients who died at pediatric age (80.95%), 3 died at adult age (14.28%), and for 1 of whom, the age of death is unknown (4.76%). Eighteen patients were White Mediterranean (European non-Finnish) (85.71%) whereas three were Amerindian (South American) (14.28%). Mortality from cardiac causes accounted for 71.42%. The second most frequent cause of death was sepsis in two patients (9.52%). One patient died from respiratory failure (4.76%) and one from renal failure (4.76%). Information regarding the cause of death was not available in two patients (9.52%). Most patients who died were diagnosed within the first week of life, the majority on the first day. This study adds additional information on mortality in one of the largest cohorts of patients with 22q11.2 rearrangements in more than 30 years of follow-up.

1 November 2014 in Anales de Pediatría (English Edition)
Verified
Journal Article
Closed access
FPF. Perin
F. Perin
MRM.M. Rodríguez Vázquez del Rey
M.M. Rodríguez Vázquez del Rey
LBLucía Deiros Bronte
Lucía Deiros Bronte
QMQ. Ferrer Menduiña
Q. Ferrer Menduiña
FNF. Rueda Nuñez
F. Rueda Nuñez
AGAlberto Galindo
Alberto Galindo